ARDELYX, INC.
Close on Oct 19, 2026
- Market cap
- $766.53M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Oct 29, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | During market hours | – | $-0.07 | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 30, 2026 | During market hours | $94.47M | $-0.15 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 19, 2026 | During market hours | $125.22M | $0.00 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 30, 2025 | During market hours | $110.30M | $0.00 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 4, 2025 | During market hours | $97.70M | $-0.08 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 1, 2025 | During market hours | $74.10M | $-0.17 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 20, 2025 | Before market open | $116.13M | $0.02 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 31, 2024 | During market hours | $98.20M | $0.00 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 2, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 22, 2024 | During market hours | – | – | – |
Company guidance
Outlook given with results on Aug 6, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| OPEX guidance | Full-year 2026 | $500.00M | New |
| revenue guidance for IBSRELA | Full-year 2026 | $350.00M to $370.00M | Raised |
| revenue guidance for XPHOZAH | Full-year 2026 | $110.00M to $120.00M | Lowered |
| IBSRELA long-term guidance | long-term | $1.00B | – |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Ardelyx filed with the SEC
Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
This presentation is intended for investor purposes only and is not intended for promotional purposes. 1Q2 2026 Earnings Q2 2026 Earnings Call August 6, 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q1 2026 Earnings Call April 30, 2026 This presentation is intended for investor purposes only and is not intended for promotional purposes.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q4 and Full Year 2025 Earnings Call February 19, 2026 This presentation is intended for investor purposes only and is not intended for promotional purposes. Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update
Results of operations · Executive or director change · Charter or bylaw amendment · EX-99.1 to Form 8-K
Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA ® Net Sales Revenue Guidance
Results of operations · EX-99.1 to Form 8-K
Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance
Results of operations · EX-99.1 to Form 8-K
Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH ® (tenapanor)
Regulation FD disclosure · EX-99.1 to Form 8-K
Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Ardelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Ardelyx Reports Third Quarter 2022 Financial
Results of operations · EX-99.1 to Form 8-K
Ardelyx Reports Second Quarter 2022 Financial
Results of operations · EX-99.1 to Form 8-K
Ardelyx Reports First Quarter 2022 Financial
Results of operations · EX-99.1 to Form 8-K
Ardelyx Reports Fourth Quarter and Full Year 2021 Financial
Results of operations · EX-99.1 to Form 8-K
Ardelyx Reports Third Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K